Looking beyond the spin of Big Pharma PR. But encouraging gossip. Come in and confide, you know you want to! “I’ll publish right or wrong. Fools are my theme, let satire be my song.”
Email: jackfriday2011(at)hotmail.co.uk
Surely Pfizer scientists have to share some of the blame for Pfizer's poor pipeline. However a much bigger share of the blame lies with management. Increasingly this also includes Kindler and Mackay. Kindler and co either sat on their pile of cash or did share buybacks and paid dividends instead of using the cash to get a pipeline. Kindler missed a golden opportunity to buy Amgen when it was trading at 40. Most of the share buybacks under Kindler have also been in the $23 range and the stock is now trading at $17. This is the second round of restructuring in the last 3 years (two of which have been under Kindler). Time for him to go.
1 comment:
Surely Pfizer scientists have to share some of the blame for Pfizer's poor pipeline. However a much bigger share of the blame lies with management. Increasingly this also includes Kindler and Mackay. Kindler and co either sat on their pile of cash or did share buybacks and paid dividends instead of using the cash to get a pipeline. Kindler missed a golden opportunity to buy Amgen when it was trading at 40. Most of the share buybacks under Kindler have also been in the $23 range and the stock is now trading at $17. This is the second round of restructuring in the last 3 years (two of which have been under Kindler). Time for him to go.
Post a Comment